Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding common stock, restricted stock units (RSUs), and stock options were converted into the right to receive the merger consideration or cancelled according to the terms of the merger agreement.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders as it represents the successful completion of a definitive merger agreement providing immediate liquidity and potential upside.

Positives

• Shareholders receive a guaranteed cash payment of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights (CVRs).
• Successful completion of the merger process as of May 14, 2026.

Negatives

• Stock options with an exercise price of $45.00 or greater were cancelled without any consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR payment is contingent upon the achievement of specific milestones, which may not be met.
• The CVRs are non-transferable, limiting liquidity for shareholders regarding the potential additional payment.

Future Outlook

The company has been acquired by Biogen and will operate as a wholly owned subsidiary; no independent future guidance is provided.

Management Comments

• The merger agreement dictates the conversion of all equity interests into cash and CVRs.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biotechnology sector, with Biogen expanding its portfolio through the acquisition of Apellis Pharmaceuticals.

Comparison to Industry Standards

• The use of CVRs in biotech acquisitions is a standard mechanism to bridge valuation gaps between buyers and sellers regarding pipeline assets.
• The $41.00 cash offer represents the final valuation for the independent entity.

Legal Proceedings

• The transaction was executed pursuant to an Agreement and Plan of Merger dated March 31, 2026.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management transition to a subsidiary of Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payments.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer